Metabolic syndrome with impaired glucose homeostasis nad prehypertension
Conditions
Interventions
Trade Name: MICARDIS 80mg, tablets
Product Name: MICARDIS 80 mg, tablets
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Sponsors
Insitute for Clinical and Experimental Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Presence of metabolic syndrome according to NCEP AT III and impaired glucose homeostasis Hypertension, pharmacologically untreated Age 30 - 65 years BMI 25 - 35 kg/m2 Patients must be able to complete all planned visits and to finish the study safely according to investigators opinion Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Diabetes mellitus Important internal disease cardiovascular, tumorous or autoimmune Thyreopathy or other important endocrine disease Drug or alcohol dependence Known hypersensitivity to IMP or to substances of similar chemical structure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the effect of telmisartan on insulin resistance measured by hyperinsulinaemic euglycaemic clamp;Secondary Objective: To monitor expressions of selected adipokines in subcutaneous adipose tissue;Primary end point(s): Insulin effect in glucose metabolism, tested by hyperinsulinaemic euglycaemic clamp | — |
Countries
Czech Republic
Outcome results
None listed